We use cookies for a better user experience. Read our Privacy Policy

I Agree

Human Reproductive Technologies Market

Human Reproductive Technologies Market (Infertility: Drugs and Procedures & Contraceptives: Drugs and Devices) - Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast, 2013 - 2019

As per a report of International Journal of Reproduction, approximately 15% of couples are reportedly suffering from infertility. This implies that 60–80 million couples experience certain reproduction complexity annually.

Late child planning, smoking, alcohol and drug abuse, and sedentary lifestyle are some of the significant risk factors. These risk factors are anticipated to increase infertility incidence in forthcoming years. As a result, demand for assisted reproductive technologies is anticipated to accelerate. This, in turn, will explicitly boost growth of human reproductive technologies market.

Rising awareness about assisted reproductive technology is one of the key factors driving growth in human reproductive technologies market. In various countries, medical associations are undertaking initiatives and implementing programs to raise awareness about infertility and related treatment.

For example, ASPIRE is an initiative on reproduction in Asia Pacific region. It aims to provide knowledge regarding human reproductive technologies throughout the region.

Such initiatives along with rising infertility rate are projected to fuel adoption rate of human technologies in coming years.

Expansion of healthcare infrastructure and availability of specialized treatment are major factors contributing to growth of the global human reproduction technologies. For example, in 2014, 77,721 human reproduction technology-based treatment procedures were performed in Australia and New Zealand.

For specialized treatment and proper attention of medical practitioner, people are opting clinics for infertility treatment. Hence, clinic segment is projected to contribute to growth of human reproduction technologies market in forthcoming years.

Meanwhile, high cost of treatment is estimated to interfere with the growth rate of human reproductive technologies market in several regions, especially in emerging economies. In addition, social and ethical concerns in developing countries may restrain adoption rate of human reproductive technologies.

Human reproductive technologies include procedures and therapies for conceiving or controlling pregnancy by means of artificial and/or semi artificial medical solutions. Reproductive technologies are used to treat infertility problems in males as well as in females. Since the last decade, a remarkable prevalence of infertility has been observed worldwide and its morbidity rate is rapidly growing. Changes in lifestyle such as delay in bearing the first child, use of contraceptive pills, increased alcohol consumption and smoking are some of the factors leading to increase in the infertility rate globally, due to which the human reproductive technologies market is experiencing rise in demand. The World Health Organization (WHO) reported that in 2010, approximately 1.9% of women aged between 20 years and 44 years were unable to have their first child and 10.5% of women who had already conceived were unable to conceive for the subsequent times. Thus, high global infertility rates will continue to provide newer growth opportunities to this market. Some other factors contributing to the growth of the human reproductive technologies market include increasing morbidity rate of infertility in both males and females, rise in awareness about the available technologies for treating problems related to reproduction, rising prevalence of unwanted pregnancies, and overall advancement in the available technologies to control reproduction.  
 
Human reproductive technologies are mainly categorized on the basis of infertility treatments and contraceptive technologies. The infertility drugs market is analyzed based on the big seven brands (by sales) such as, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn. Viagra, Gonal-f and AndroGel are the major drugs in their respective drug classes, which are preferred majorly for treating different causes of infertility. Further, the human reproductive technologies market is analyzed by various infertility treatment procedures which is led by the intrauterine insemination (IUI) procedure owing to low procedural cost and less complexity in performing the procedure. 
 
Contraceptive technologies market is segmented into contraceptive drugs such as oral contraceptive pills, contraceptive injectables and topical contraceptives; and devices such as male and female contraceptive devices. Within the contraceptives market, the market share of male contraceptives was the largest due to factors such as ease of use, lack of side effects and higher availability. The market will be driven by factors such as increase in conception rate, rising prevalence of unwanted pregnancies and sexually transmitted diseases (STDs).
 
The global human reproductive technologies market is highly fragmented in nature with many companies currently competing in the market. Well established market players such as Merck & Co., Inc., Ferring International Center S.A., Pfizer, Inc. Merck Serono and Bayer AG dominate this market with their proprietary products and predatory growth strategies. Patent repositories of the established market players are restraining the entry and growth of new players entering the market. 
 
Geographically, North America dominates the global human reproductive technologies market and is followed by Europe. Important factors that have led to rise in infertility incidence in North America include high obesity rates, rising age of conception and hazards emerging from shift in lifestyle. Women become less fertile at around 30 years of age and this rate speeds up after 35 years of age. Asia-Pacific is expected to show the highest growth rate in the human reproductive technologies market owing to factors such as highest population in the world, increasing awareness about reproductive technologies and increasing disposable income of the population in this region. One of the major issues restraining the market in emerging economies is the lack of initiatives to consult a specialist for reproductive disorders. However, rapid adoption of western lifestyle and rising incidence of hypertension is affecting the ability to conceive and thus, driving the demand for infertility drugs and devices in this region.
Human Reproductive Technologies Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Table of Contents
 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.4 Research Methodology
1.5 List of Abbreviations
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Human Reproductive Technologies Market
2.2 Comparative Analysis: Global Human Reproductive Technologies Market, by Geography, 2012 & 2019 (Value %)
 
Chapter 3 Market Overview
3.1 Introduction and Market Definition
      3.1.1 Infertility Causative Factors
3.2 Market Drivers
      3.2.1 Delay in Conception
      3.2.2 Rise in the Number of Infertile Population
      3.2.3 Increasing Prevalence of Worldwide Obesity
      3.2.4 Lifestyle Hazards such as Smoking, Stress and Pollution
      3.2.5 Rising Prevalence of Unwanted Pregnancies and High Global Prevalence of Women with Unmet Contraceptive Needs
      3.2.6 Government and NGO Initiatives to Promote Contraceptive Products
      3.2.7 Implementation of the Patient Protection Act or the Affordable Care Act
3.3 Market Restraints
      3.3.1 Limited Insurance Coverage
      3.3.2 Economic and Social Factors
      3.3.3 Side Effects Associated with the Use of Contraceptive Drugs and Devices
3.4 Market Opportunities
      3.4.1 Rise in Medical Tourism
      3.4.2 Government Support for Infertility Procedures
      3.4.3 Presence of Strong Contraceptives Pipeline
3.5 Porter’s Five Forces Analysis for the Global Human Reproductive Technologies Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyers
      3.5.3 Threat of New Entrants
      3.5.4 Threat of Substitutes
      3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis: Global Human Reproductive Technologies Market, by Geography
 
Chapter 4 Global Human Reproduction Technologies Market, by Infertility Treatment
4.1 Overview
4.2 Infertility Drugs
      4.2.1 Global Infertility Drugs Market Revenue, by Brand, 2011 – 2019 (USD Million)
      4.2.2 Gonal-f
               4.2.2.1 Global Gonal-f Market Revenue, 2011 – 2019 (USD Million)
      4.2.3 Follistim AQ
              4.2.3.1 Global Follistim AQ Market Revenue, 2011 – 2019 (USD Million)
      4.2.4 AndroGel
              4.2.4.1 Global AndroGel Market Revenue, 2011 – 2019 (USD Million)
      4.2.5 Testim
              4.2.5.1 Global Testim Market Revenue, 2011 – 2019 (USD Million)
      4.2.6 Viagra
              4.2.6.1 Global Viagra Market Revenue, 2011 – 2019 (USD Million)
      4.2.7 Cialis
              4.2.7.1 Global Cialis Market Revenue, 2011 – 2019 (USD Million)
      4.2.8 Levitra/Staxyn
              4.2.8.1 Global Levitra/Staxyn Market Revenue, 2011 – 2019 (USD Million)
4.3 Infertility Treatment/Assisted Reproductive Technologies (ART)
      4.3.1 Global Infertility Treatment/ART Procedures Market Forecast, by Procedures, 2011 – 2019 (Number of Procedures)
      4.3.2 In Vitro Fertilization (IVF)
              4.3.2.1 Global IVF Procedures Market Forecast, 2011 – 2019 (Number of Procedures)
      4.3.3 Intracytoplasmic Sperm Injection (ICSI)
              4.3.3.1 Global ICSI Procedures Market Forecast, 2011 – 2019 (Number of Procedures)
      4.3.4 Zygote Intrafallopian Transfer (ZIFT)
              4.3.4.1 Global ZIFT Procedures Market Forecast, 2011 – 2019 (Number of Procedures)
      4.3.5 Gamete Intrafallopian Transfer (GIFT)
              4.3.5.1 Global GIFT Procedures Market Forecast, 2011 – 2019 (Number of Procedures)
      4.3.6 Intrauterine Insemination (IUI)
              4.3.6.1 Global IUI Procedures Market Forecast, 2011 – 2019 (Number of Procedures)
 
Chapter 5 Global Human Reproductive Technologies Market, by Contraceptive Technologies
5.1 Overview
      5.1.1 Global Contraceptives Market Revenue, by Product Type, 2011 - 2019 (USD Million)
5.2 Contraceptive Drugs
      5.2.1 Global Contraceptive Drugs Market Revenue, by Type, 2011 – 2019 (USD Million)
      5.2.2 Oral Contraceptive Pills 
               5.2.2.1 Global Oral Contraceptive Pills Market Revenue, 2011 – 2019 (USD Million)
      5.2.3 Contraceptive Injectables
              5.2.3.1 Global Contraceptive Injectables Market Revenue, 2011 – 2019 (USD Million)
      5.2.4 Topical Contraceptives
              5.2.4.1 Global Topical Contraceptives Market Revenue, 2011 – 2019 (USD Million)
5.3 Contraceptive Devices
      5.3.1 Global Contraceptive Devices Market Revenue, by Type, 2011 – 2019 (USD Million)
      5.3.2 Male Contraceptive Devices (Male Condoms)
              5.3.2.1 Global Male Contraceptive Devices (Male Condoms) Market Revenue, 2011 – 2019 (USD Million)
      5.3.3 Female Contraceptive Devices
              5.3.3.1 Global Female Contraceptive Devices Market Revenue, 2011 – 2019 (USD Million)
 
Chapter 6 Global Human Reproductive Technologies Market Revenue, by Geography
6.1 Overview
6.2 North America
      6.2.1 North America Human Reproductive Technologies Market Revenue, by Technology, 2011 – 2019 (USD Million)
      6.2.2 North America Human Reproductive Technologies Market Revenue, 2011 – 2019 (USD Million)
6.3 Europe
      6.3.1 Europe Human Reproductive Technologies Market Revenue, by Technology, 2011 – 2019 (USD Million)
      6.3.2 Europe Human Reproductive Technologies Market Revenue, 2011 – 2019 (USD Million)
6.4 Asia-Pacific
      6.4.1 Asia-Pacific Human Reproductive Technologies Market Revenue, by Technology, 2011 – 2019 (USD Million)
      6.4.2 Asia-Pacific Human Reproductive Technologies Market Revenue, 2011 – 2019 (USD Million)
6.5 Rest of the World (RoW)
      6.5.1 RoW Human Reproductive Technologies Market Revenue, by Technology, 2011 – 2019 (USD Million)
      6.5.2 RoW Human Reproductive Technologies Market Revenue, 2011 – 2019 (USD Million)
 
Chapter 7 Recommendations
 
Chapter 8 Company Profiles
8.1 Abbott Laboratories, Inc.
      8.1.1 Company Overview
      8.1.2 Financial Overview
      8.1.3 Product Portfolio
      8.1.4 Business Strategies
      8.1.5 Recent Developments
8.2 Actavis, Inc.
      8.2.1 Company Overview
      8.2.2 Financial Overview
      8.2.3 Product Portfolio
      8.2.4 Business Strategies
      8.2.5 Recent Developments
8.3 Bayer AG
      8.3.1 Company Overview
      8.3.2 Financial Overview
      8.3.3 Product Portfolio
      8.3.4 Business Strategies
      8.3.5 Recent Developments
8.4 Church & Dwight, Co. Inc.
      8.4.1 Company Profile
      8.4.2 Financial Overview
      8.4.3 Product Portfolio
      8.4.4 Business Strategies
      8.4.5 Recent Developments
8.5 Cook Medical, Inc.
      8.5.1 Company Overview      
      8.5.2 Product Portfolio
      8.5.3 Business Strategies
      8.5.4 Recent Developments
8.6 Ferring International Center S.A.
      8.6.1 Company Overview
      8.6.2 Product Portfolio
      8.6.3 Business Strategies
      8.6.4 Recent Developments
8.7 Johnson & Johnson
      8.7.1 Company Overview
      8.7.2 Financial Overview
      8.7.3 Product Portfolio
      8.7.4 Business Strategies
      8.7.5 Recent Developments
8.8 Merck & Co., Inc.
      8.8.1 Company Overview
      8.8.2 Financial Overview
      8.8.3 Product Portfolio
      8.8.4 Business Strategies
      8.8.5 Recent Developments
8.9 Merck Serono
      8.9.1 Company Overview
      8.9.2 Financial Overview
      8.9.3 Product Portfolio
      8.9.4 Business Strategies
      8.9.5 Recent Developments
8.10 Pfizer, Inc.
      8.10.1 Company Overview
      8.10.2 Financial Overview
      8.10.3 Product Portfolio
      8.10.4 Business Strategies
      8.10.5 Recent Developments
8.11 Reckitt Benckiser Group plc
      8.11.1 Company Overview
      8.11.2 Financial Overview
      8.11.3 Product Portfolio
      8.11.4 Business Strategies
      8.11.5 Recent Developments
8.12 Teva Pharmaceutical Industries Ltd.
      8.12.1 Company Overview
      8.12.2 Financial Overview
      8.12.3 Product Portfolio
      8.12.4 Business Strategies
      8.12.5 Recent Developments
8.13 Warner Chilcott plc
      8.13.1 Company Overview
      8.13.2 Financial Overview      
      8.13.3 Product Portfolio
      8.13.4 Business Strategies
      8.13.5 Recent Developments
List of Tables
 
TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Global Human Reproductive Technologies Market
TABLE 3 Side Effects Associated with the Use of Contraceptive Drugs and Devices
TABLE 4 Global Infertility Drugs Market Revenue, by Brand, 2011 – 2019 (USD Million)
TABLE 5 Global Infertility Treatment/ART Procedures Market Forecast, by Procedures, 2011 – 2019 (Number of Procedures)
TABLE 6 Global Contraceptives Market Revenue, by Product Type, 2011 - 2019 (USD Million)
TABLE 7 Global Contraceptive Drugs Market Revenue, by Type, 2011 – 2019 (USD Million)
TABLE 8 List of Latest Oral Contraceptive Pill Approvals, 2010 – 2012
TABLE 9 Global Contraceptive Devices Market Revenue, by Type, 2011 – 2019 (USD Million)
TABLE 10 North America Human Reproductive Technologies Market Revenue, by Technology, 2011 – 2019 (USD Million)
TABLE 11 Europe Human Reproductive Technologies Market Revenue, by Technology, 2011 – 2019 (USD Million)
TABLE 12 Asia-Pacific Human Reproductive Technologies Market Revenue, by Technology, 2011 – 2019 (USD Million)
TABLE 13 RoW Human Reproductive Technologies Market Revenue, by Technology, 2011 – 2019 (USD Million)

List of Figures

 

FIG. 1 Human Reproductive Technologies Market Segmentation

FIG. 2 Global Human Reproductive Technologies Market, by Infertility Drugs, 2011 - 2019 (USD Million)

FIG. 3 Global Human Reproductive Technologies Market, by Infertility Treatment Procedures, 2012 (Number of Procedures)

FIG. 4 Comparative Analysis: Global Human Reproductive Technologies Market, by Geography, 2012 & 2019 (Value %)

FIG. 5 Infertility Causative Factors: CDC, 2011 (%)

FIG. 6 Porter’s Five Forces Analysis: Global Human Reproductive Technologies Market

FIG. 7 Market Attractiveness Analysis: Global Human Reproductive Technologies Market, by Geography

FIG. 8 Global Gonal-f Market Revenue, 2011 – 2019 (USD Million)

FIG. 9 Global Follistim AQ Market Revenue, 2011 – 2019 (USD Million)

FIG. 10 Global AndroGel Market Revenue, 2011 – 2019 (USD Million)

FIG. 11 Global Testim Market Revenue, 2011 – 2019 (USD Million)

FIG. 12 Global Viagra Market Revenue, 2011 – 2019 (USD Million)

FIG. 13 Global Cialis Market Revenue, 2011 – 2019 (USD Million)

FIG. 14 Global Levitra/Staxyn Market Revenue, 2011 – 2019 (USD Million)

FIG. 15 Global IVF Procedures Market Forecast, 2011 – 2019 (Number of Procedures)

FIG. 16 Global ICSI Procedures Market Forecast, 2011 – 2019 (Number of Procedures)

FIG. 17 Global ZIFT Procedures Market Forecast, 2011 – 2019 (Number of Procedures)

FIG. 18 Global GIFT Procedures Market Forecast, 2011 – 2019 (Number of Procedures)

FIG. 19 Global IUI Procedures Market Forecast, 2011 – 2019 (Number of Procedures)

FIG. 20 Global Oral Contraceptive Pills Market Revenue, 2011 – 2019 (USD Million)

FIG. 21 Global Contraceptive Injectables Market Revenue, 2011 – 2019 (USD Million)

FIG. 22 Global Topical Contraceptives Market Revenue, 2011 – 2019 (USD Million)

FIG. 23 Global Male Contraceptive Devices (Male Condoms) Market Revenue, 2011 – 2019 (USD Million)

FIG. 24 Global Female Contraceptive Devices Market Revenue, 2011 – 2019 (USD Million)

FIG. 25 North America Human Reproductive Technologies Market Revenue, 2011 – 2019 (USD Million)

FIG. 26 Europe Human Reproductive Technologies Market Revenue, 2011 – 2019 (USD Million)

FIG. 27 Asia-Pacific Human Reproductive Technologies Market Revenue, 2011 – 2019 (USD Million)

FIG. 28 RoW Human Reproductive Technologies Market Revenue, 2011 – 2019 (USD Million)

FIG. 29 Abbott Laboratories, Inc.: Annual Revenue, 2010 – 2012 (USD Million)

FIG. 30 Actavis, Inc.: Annual Revenue, 2010 – 2012 (USD Million)

FIG. 31 Bayer AG: Annual Revenue, 2010 – 2012 (USD Million)

FIG. 32 Church & Dwight Co. Inc.: Annual Revenue, 2010 – 2012 (USD Million)

FIG. 33 Johnson & Johnson: Annual Revenue, 2010 – 2012 (USD Million)

FIG. 34 Merck & Co., Inc. (Pharmaceutical Division): Annual Revenue, 2010 – 2012 (USD Million)

FIG. 35 Merck Serono: Annual Revenue, 2010 – 2012 (USD Million)

FIG. 36 Pfizer, Inc.: Annual Revenue, 2010 – 2012 (USD Million)

FIG. 37 Reckitt Benckiser Group plc: Annual Revenue, 2010 - 2012 (USD Million)

FIG. 38 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2010 – 2012 (USD Million)

FIG. 39 Warner Chilcott plc: Annual Revenue, 2010 - 2011 (USD Million)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

420

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved